An Ontario-based mushroom company has teamed up with Arizona State University to advance psychedelic genome research. Researchers hope to make breakthroughs in personalized medicine.
The research project seeks to advance precision medicine by identifying biomarkers and their psilocybin responses.
The recruitment process for the study asks the mushroom company, Red Light Holland, to hand out research materials to customers and gives licensed therapists the ability to refer clients.
Candace Lewis is the ASU assistant professor affiliated with the project.
“So this initiative came out of my lab and it's the idea that genomic science is definitely the path forward. Like it's the new frontier in understanding complex behaviors and complex disorders like psychiatric disorders," she said.
Red Light Holland says the study is significant amid a growing legalization of psychedelics on the global level. Possession of psilocybin remains illegal in Arizona.
-
John Galgiani, director of the Valley Fever Center for Excellence at the University of Arizona, joined The Show to talk more about it. -
The Indian Health Service’s Tucson Area Office serves more than 28,000 tribal members from the Pascua Yaqui, Tohono O’odham Nation and other tribes. -
Peptides are everywhere right now — especially in the wellness world. So, are peptides the future of aging — or is there more we should know about them? -
A drug-resistant fungal infection that can infect blood, wounds and other parts of the body is spreading in Arizona and other states. -
It's a lesson every doctor learns eventually: Don’t always assume that what you see tells the whole story. Medical commentator Dr. Joseph Sirven explains.
